Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rebecca Redman

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 22, 2009
Safety of intravenous infusion of doripenemRebecca Redman, Thomas M File
Expert Opinion on Investigational Drugs|August 2, 2002
Iseganan HCl: a novel antimicrobial agentFrancis J Giles, Rebecca Redman, Salim Yazji, et al.
International Journal of Antimicrobial Agents|February 16, 2013
Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trialsDennis A K Rice, Koné Kaniga, Michael Lee, et al.
Antimicrobial Agents and Chemotherapy|January 5, 2011
Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenemIolanda Cirillo, Nicole Vaccaro, Dainius Balis, et al.
Drug Safety|August 13, 2009
Overview of seizure-inducing potential of doripenemGeorge G Zhanel, Nzeera Ketter, Ethan Rubinstein, et al.
Medical Oncology (Northwood, London, England)|November 2, 2019
Correction to: Outcomes of hypercalcemia of malignancy in patients with solid cancer: a national inpatient analysisShruti Bhandari, Rohit Kumar, Prashant Tripathi, et al.
Advances in Therapy|April 17, 2016
Exposure-Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I StudySathej Gopalakrishnan, Amit Khatri, Sven Mensing, et al.
Journal of Clinical Pharmacology|June 26, 2009
Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteersIolanda Cirillo, Nicole Vaccaro, Kenneth Turner, et al.
Journal of Clinical Pharmacology|December 17, 2011
Pharmacokinetics of single-dose doripenem in adults with cystic fibrosisIolanda Cirillo, Nicole Vaccaro, Rebecca Redman, et al.
Medical Oncology (Northwood, London, England)|September 19, 2019
Outcomes of hypercalcemia of malignancy in patients with solid cancer: a national inpatient analysisShruti Bhandari, Rohit Kumar, Prashant Tripathi, et al.
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 22, 2009
Safety of intravenous infusion of doripenemRebecca Redman, Thomas M File
Expert Opinion on Investigational Drugs|August 2, 2002
Iseganan HCl: a novel antimicrobial agentFrancis J Giles, Rebecca Redman, Salim Yazji, et al.
International Journal of Antimicrobial Agents|February 16, 2013
Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trialsDennis A K Rice, Koné Kaniga, Michael Lee, et al.
Antimicrobial Agents and Chemotherapy|January 5, 2011
Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenemIolanda Cirillo, Nicole Vaccaro, Dainius Balis, et al.
Drug Safety|August 13, 2009
Overview of seizure-inducing potential of doripenemGeorge G Zhanel, Nzeera Ketter, Ethan Rubinstein, et al.
Medical Oncology (Northwood, London, England)|November 2, 2019
Correction to: Outcomes of hypercalcemia of malignancy in patients with solid cancer: a national inpatient analysisShruti Bhandari, Rohit Kumar, Prashant Tripathi, et al.
Advances in Therapy|April 17, 2016
Exposure-Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I StudySathej Gopalakrishnan, Amit Khatri, Sven Mensing, et al.
Journal of Clinical Pharmacology|June 26, 2009
Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteersIolanda Cirillo, Nicole Vaccaro, Kenneth Turner, et al.
Journal of Clinical Pharmacology|December 17, 2011
Pharmacokinetics of single-dose doripenem in adults with cystic fibrosisIolanda Cirillo, Nicole Vaccaro, Rebecca Redman, et al.
Medical Oncology (Northwood, London, England)|September 19, 2019
Outcomes of hypercalcemia of malignancy in patients with solid cancer: a national inpatient analysisShruti Bhandari, Rohit Kumar, Prashant Tripathi, et al.
Pageof 5